



Trends in Thrombolytic Use for Ischemic Stroke in the United States

Citation

Fang, Margaret C., David M. Cutler, and Allison B. Rosen. 2010. Trends in thrombolytic use for ischemic stroke in the United States. *Journal of Hospital Medicine* 5(7): 406-9.

Published Version

doi:10.1002/jhm.689

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:5343031>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Trends in Thrombolytic Use for Ischemic Stroke in the United States

Margaret C. Fang, MD, MPH¹

David M. Cutler, PhD^{2,3}

Allison B. Rosen, MD, MPH, ScD⁴

Corresponding Author:

Margaret C. Fang, MD, MPH

University of California, San Francisco

Division of Hospital Medicine

533 Parnassus Ave., Box 0131

San Francisco, CA 94143

Phone: (415) 502-7100

Fax: (415) 514-2094

Email: mfang@medicine.ucsf.edu

¹ University of California, San Francisco Department of Medicine (San Francisco, CA)

² Harvard University Department of Economics and Kennedy School of Government (Cambridge, MA)

³ National Bureau of Economic Research (Cambridge, MA)

⁴ University of Michigan Department of Medicine (Ann Arbor, MI)

Acknowledgments

We would like to thank Mr. Loren Yglecias for his assistance with manuscript text and references.

Funding

This work was supported by a National Institute on Aging grant P01 AG17625. Dr. Fang was supported by a National Institute on Aging Paul B. Beeson Career Development Award AG028978.

Conflicts of Interest/Disclosures

None of the authors have significant conflicts of interest to disclose

1
2
3 Title: **Trends in Thrombolytic Use for Ischemic Stroke in the United States**

4
5
6 Cover title: **Trends in thrombolytic use for stroke**

7
8 Text word count: 1560

9
10 Tables: 2

11
12 Figures: 1

13
14
15 Index terms: Acute stroke, Ischemic stroke, Outcomes Measurement, Quality Improvement,

16
17
18 Tissue plasminogen activator, Thrombolysis

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

ABSTRACT

Background

Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic stroke, prior studies have found low rates of administration. Recent guidelines and regulatory agencies have advocated for increased tPA administration in appropriate patients, but it is unclear how many patients actually receive tPA.

Objective

To determine whether national rates of tPA use for ischemic stroke have increased over time.

Methods

We identified all patients with a primary diagnosis of ischemic stroke from years 2001-2006 in the National Hospital Discharge Survey, a nationally representative sample of inpatient hospitalizations, and searched for procedure codes for intravenous thrombolytic administration. Clinical and demographic factors were obtained from the survey and multivariable logistic regression used to identify independent predictors associated with thrombolytic use.

Results

Among the 22,842 patients hospitalized with ischemic stroke, tPA administration rates increased from 0.87% in 2001 to 2.40% in 2006 ($p < 0.001$ for trend). Older patients were less likely to receive tPA (adjusted odds ratio and 95% confidence interval (OR) = 0.4 [0.3-0.6] for patients \geq 80 years vs. $<$ 60 years), as were African-American patients (OR=0.4 [0.3-0.7]). Larger hospitals were more likely to administer tPA (OR=3.3 [2.0-5.6] in hospitals with at least 300 beds compared to those with 6-99 beds).

Conclusions

1
2
3 Although tPA administration for ischemic stroke has increased nationally in recent years, the
4 overall rate of use remains very low. Larger hospitals were more likely to administer tPA.
5
6

7
8 Further efforts to improve appropriate administration of tPA should be encouraged, particularly
9
10 as the acceptable time-window for using tPA widens.
11
12

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Background

Recombinant tissue plasminogen activator (tPA), approved for use in the United States for the treatment for acute ischemic stroke since 1996, improves overall outcomes from ischemic stroke when administered to selected patients¹⁻⁴. Several prominent guidelines, including the Brain Attack Coalition and the American Stroke Association, have recommended increasing the use of tPA for acute ischemic stroke⁵⁻⁷. In addition, in 2003 the Joint Commission on Accreditation of Healthcare Organizations developed a disease-specific certification program to designate certain institutions “Primary Stroke Centers”, with one of the performance measures being the availability of thrombolysis⁸.

Despite guidelines and regulatory agencies promoting the use of thrombolysis for ischemic stroke, previous studies have shown disappointingly low rates of use⁹⁻¹². The goals of this study were to assess whether national trends in the use of thrombolysis for acute ischemic stroke have increased in light of increased regulatory activity as well as to identify patient characteristics associated with thrombolytic administration.

Materials and Methods

Data for this study were obtained from the 2001 through 2006 National Hospital Discharge Survey (NHDS), a nationally representative sample of inpatient hospitalizations conducted annually by the National Center for Health Statistics¹³. The NHDS collects data from approximately 300,000 patients from about 500 short-stay nonfederal hospitals in the United States and uses a 3 stage sampling strategy that allows for extrapolation to national level estimates. Response rates typically exceed 90% from participating hospitals. The survey collects demographic data, including age, sex, race, hospital geographic region, hospital bedsize and

1
2
3 patient insurance status. In addition, up to 7 diagnostic and 4 procedural codes from the
4
5 hospitalization are available, as is hospitalization length of stay and patient discharge disposition.
6
7 No information on timing of symptoms, degree of neurologic compromise, or results of imaging
8
9 tests were available in the NHDS.
10
11

12 We searched for all patients aged 18 years or older with a primary diagnostic code of
13
14 ischemic stroke using the *International Classification of Diseases, 9th Edition, Clinical*
15
16 *Modification* (ICD-9-CM) codes 433, 434, 436, 437.0, and 437.1, excluding codes with a fifth
17
18 digit of 0 (which indicated arterial occlusion without mention of cerebral infarction). We then
19
20 searched for the presence of an ICD-9-CM procedure code for injection or infusion of
21
22 thrombolytic agent (code 99.10). Specific comorbid conditions associated with ischemic stroke
23
24 were identified by searching for specific ICD-9-CM codes, including for heart failure, coronary
25
26 artery disease, hypertension, diabetes mellitus, and atrial fibrillation. To provide a general
27
28 assessment of the severity of illness of the patients, we calculated an adapted Charlson
29
30 comorbidity score for each patient using available secondary discharge diagnosis codes¹⁴. We
31
32 also searched for codes corresponding to intracranial hemorrhage, a complication associated with
33
34 tPA administration.
35
36
37
38
39
40
41
42

43 *Statistical Analysis*

44
45 We defined thrombolytic utilization rates as the number of patients hospitalized with a
46
47 primary diagnosis of ischemic stroke who had a procedure code for thrombolysis divided by the
48
49 total number of patients hospitalized with ischemic stroke. To calculate nationally representative
50
51 prevalence rates, we used the sample weights provided by the NHDS to account for the complex
52
53 sampling design of the survey. Differences in thrombolytic administration rates by patient and
54
55
56
57
58
59
60

1
2
3 hospital characteristics were tested using chi-squared tests for categorical variables and t-tests for
4
5 continuous variables. Variables underwent a backwards selection process with a significance
6
7 level of 0.05 to develop the final multivariable model of predictors of thrombolytic
8
9 administration. Length of stay and hospital discharge status were not included in the variable
10
11 selection process, as the focus was on predictors of initial administration of thrombolytics. All
12
13 analyses were conducted using SAS Version 9.1 (SAS Institute Inc., Cary, NC).
14
15
16
17
18
19

20 21 Results

22
23 From years 2001 through 2006, we identified 22,842 patients with a primary diagnosis of
24
25 ischemic stroke. Of these, 313 (1.37%, 95% confidence interval [CI]: 1.22%-1.53%) had a
26
27 procedure code for injection or infusion of thrombolysis. Using NHDS sample weights, these
28
29 numbers corresponded to an estimated 2.55 million hospitalizations for ischemic stroke in the
30
31 United States during the time period and to 35,082 patients receiving intravenous thrombolytics.
32
33 Although the overall rate of thrombolysis administration was quite low overall, the
34
35 administration rate increased over time, from 0.87% [95%CI: 0.61%-1.22%] of stroke patients in
36
37 year 2001 to 2.40% [95%CI: 1.95-2.93%] in year 2006 and with a particular increase especially
38
39 noted after year 2003 ($p < 0.001$ for trend, **Figure 1**).
40
41
42
43

44
45 On bivariate analysis, a lower proportion of African-American patients received tPA
46
47 compared to white patients (0.8% vs. 1.5%, $p = 0.003$), while a higher proportion of patients with
48
49 atrial fibrillation received tPA (2.3% vs. 1.2%, $p < 0.001$). Older patients were less likely than
50
51 younger patients to receive tPA (**Table 1**). The rate of intracranial hemorrhage was significantly
52
53 higher in patients who received tPA (5.4% vs. 0.6%, $p < 0.001$) and the overall inpatient mortality
54
55 in patients who received tPA was 9.0%. Mortality in patients receiving tPA continued to be
56
57
58
59
60

1
2
3 higher than in patients who did not receive tPA even when patients with intracranial hemorrhage
4
5 were excluded (8.1% vs. 5.3%, $p < 0.001$). Larger hospitals were more likely to administer tPA to
6
7 patients with ischemic stroke, with a 1.79% administration rate in hospitals with ≥ 300 beds
8
9 compared to 0.90% in hospitals with 100-199 beds and 0.52% in hospitals with 6-99 beds
10
11 (p<0.001).
12
13

14
15 After adjusting for patient and hospital characteristics, the absolute rate of thrombolysis
16
17 administration increased by an average of 0.19% per year [95% confidence interval 0.12%-
18
19 0.26%]. Factors that were significantly associated with administration of thrombolytics included
20
21 being hospitalized in a larger hospital, having a history of atrial fibrillation, and a higher
22
23 Charlson comorbidity index (**Table 2**). Patients aged 80 years or older, African-American
24
25 patients, and those with diabetes mellitus were significantly less likely to receive thrombolysis.
26
27
28
29
30
31

32 Discussion

33
34 Despite strong recommendations from guidelines and regulatory agencies, national rates
35
36 of intravenous thrombolysis for ischemic stroke continue to be quite low overall. However, tPA
37
38 administration appears to have increased from previous years and particularly increased in years
39
40 after the Joint Commission began to accredit institutions as “Primary Stroke Centers”¹¹. The
41
42 oldest patients and African-Americans were less likely to receive thrombolytics, while patients
43
44 with atrial fibrillation were more likely to receive thrombolysis, potentially related to atrial
45
46 fibrillation causing more severe strokes¹⁵. Five point four percent of patients who received tPA
47
48 were diagnosed with intracranial hemorrhage, and the inpatient mortality rate of patients with
49
50 tPA was 9.0%.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The exact optimal rate of thrombolysis administration for the patients in our study is
5
6 unknown, as the NHDS database lacked detailed information on factors that would preclude tPA
7
8 administration such as late timing of presentation and mild stroke symptoms³. Studies conducted
9
10 in stroke registries and regional settings have found that only approximately 15%-32% of
11
12 patients presenting with ischemic stroke arrive within 3 hours of symptom onset, and of these,
13
14 only about 40%-50% are eligible for tPA clinically^{9, 10, 16-19}. However, even among presumed
15
16 eligible patients, tPA administration rates only range between 25% and 43%^{17, 19, 20}, and the ideal
17
18 rate is likely to be higher than the very low rates we observed in our study. Newer evidence that
19
20 extending the time window where tPA may be given safely may increase the number of eligible
21
22 patients²¹.
23
24
25

26
27 Patients who received thrombolysis had higher mortality rates than patients who did not.
28
29 Although we were unable to determine a causal association, prior observational studies of tPA
30
31 administration for acute stroke have found that patients with more severe neurologic deficits
32
33 were more likely to receive thrombolysis^{17,18}. The 9.0% inpatient case-fatality rate observed in
34
35 our study compares favorably to the 13.4% mortality rate after tPA reported in a post-approval
36
37 meta-analysis of safety outcomes²² and the rate of intracranial hemorrhage in our analysis was
38
39 similar to those observed in other settings^{9, 22-25}. We were unable to determine whether
40
41 intracranial hemorrhages in our study were as a result of tPA administration or whether patients
42
43 who received tPA were more likely to have intracranial hemorrhages detected, such as may be
44
45 due to increased frequency of head imaging.
46
47
48
49

50
51 Larger hospitals were more likely to administer tPA. This may reflect regionalization of
52
53 stroke care, particularly in those designated as stroke “centers of excellence”. As well, there is
54
55 some evidence that there is a “learning curve” with thrombolysis administration, where
56
57
58
59
60

1
2
3 guideline-recommended practice and use of tPA increases with additional experience with the
4
5 drug^{9, 26}. Promoting systems that allow for rapid triage and diagnosis of acute stroke should be
6
7 encouraged and hospital leaders should develop strategies that allow for early recognition of
8
9 potential tPA candidates.
10
11


12
13 There are several limitations to our analysis. The NHDS does not collect detailed data on
14
15 clinical or presenting features of stroke, and so we lacked information on stroke severity and
16
17 eligibility for administration of thrombolysis. Our study may have underestimated the overall
18
19 rates of thrombolysis, as it was dependent on diagnostic codes. A previous study of 34 patients
20
21 who received tPA found that although the 99.10 code was 100% specific, the code identified
22
23 only 17 patients who actually received tPA (sensitivity of 50%)²⁰. Another study comparing
24
25 Medicare administrative claims data to actual pharmacy billing charges for tPA found that
26
27 administrative data underestimated the rate of tPA administration by about 25%-30%¹². If a
28
29 diagnostic code sensitivity of 50% was assumed, rates of tPA administration in our study may
30
31 have been as high as 4.8% [95% CI: 4.1%-5.5%] by year 2006.
32
33
34
35

36
37 In conclusion, the use of intravenous thrombolysis in patients admitted with acute
38
39 ischemic stroke in the United States has risen over time, but overall use remains very low.
40
41 Further efforts to improve appropriate administration rates should be encouraged, particularly as
42
43 the acceptable time-window for using tPA widens.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Figure 1. Proportion of patients admitted with a primary diagnosis of ischemic stroke who
4 received thrombolysis
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



View Only

Table 1. Clinical characteristics of 22,842 patients with a primary diagnosis of ischemic stroke

	Thrombolysis N (%)	No thrombolysis N (%)	P value
Age			0.001
< 60	76 (24.3)	4478 (19.9)	
60-69	73 (23.3)	3942 (17.5)	
70-79	82 (26.2)	6265 (27.8)	
80+	82 (26.2)	7844 (34.8)	
Female	155 (49.5)	12625 (56.0)	0.02
Race			0.003
White	173 (55.3)	11542 (51.2)	
African-American	29 (9.3)	3774 (16.8)	
Other	16 (5.1)	814 (3.6)	
Not stated	95 (30.4)	6399 (28.4)	
Region			0.05
Northeast	78 (24.9)	4570 (20.3)	
Midwest	84 (26.8)	6924 (30.7)	
South	104 (33.2)	8284 (36.8)	
West	47 (15.0)	2751 (12.2)	
Type of admission			<0.001
Emergent	247 (78.9)	14233 (63.2)	
Urgent	33 (10.5)	3703 (16.4)	
Elective	5 (1.6)	1346 (6.0)	
Unknown	28 (9.0)	3247 (14.4)	
Length of stay, days [95% CI]	7.2 [6.6-7.8]	6.0 [5.9-6.1]	<0.001
Hospital bedsize			<0.001
6-99	16 (5.1)	3065 (13.6)	
100-199	48 (15.3)	5289 (23.5)	
200-299	86 (27.5)	5212 (23.1)	
300+	163 (52.1)	8963 (39.8)	

1				
2				
3				
4	Payment type			<0.001
5	Medicare	176 (56.2)	15197 (67.5)	
6	Medicaid	21 (6.7)	1245 (5.5)	
7	Private	45 (14.4)	2483 (11.0)	
8	HMO/PPO	39 (12.5)	2224 (9.9)	
9	Other/unknown	32 (10.2)	1380 (6.1)	
10				
11	Discharge status			<0.001
12	Home	98 (31.3)	9507 (42.2)	
13	Short term care facility	25 (8.0)	1271 (5.6)	
14	Long term care facility	62 (19.8)	5400 (24.0)	
15	Alive, status unknown	89 (28.4)	4514 (20.0)	
16	Death	28 (9.0)	1218 (5.4)	
17	Unknown	11 (3.5)	619 (2.8)	
18				
19	Comorbid conditions			
20	Congestive heart failure	48 (15.3)	2769 (12.3)	0.10
21	Coronary artery disease	49 (15.7)	4082 (18.1)	0.26
22	Hypertension	164 (52.4)	12480 (55.4)	0.29
23	Diabetes mellitus	42 (13.4)	4965 (22.0)	<0.001
24	Atrial fibrillation	96 (30.7)	4096 (18.2)	<0.001
25	Intracranial hemorrhage	17 (5.4)	139 (0.6)	<0.001
26				
27	Charlson score (mean)	2.48 [2.32-2.64]	2.38 [2.36-2.40]	0.23
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

Table 2. Independent predictors of receiving thrombolysis in 22,842 hospitalized patients with a primary diagnosis of ischemic stroke

Characteristic	Adjusted odds ratio and 95% confidence intervals
Year (per year, from 2001 to 2006)	1.2 [1.1-1.3]
Age	
<60	Referent
60-69	1.0 [0.7-1.4]
70-79	0.6 [0.5-0.9]
80+	0.4 [0.3-0.6]
Race	
Not African-American	Referent
African-American	0.4 [0.3-0.7]
Unknown	1.0 [0.8-1.2]
Hospital bedsize	
6-99	Referent
100-199	1.7 [1.0-3.1]
200-299	3.2 [1.8-5.4]
300+	3.3 [2.0-5.6]
Diabetes mellitus	0.5 [0.3-0.6]
Atrial fibrillation	2.2 [1.7-2.9]
Charlson comorbidity score ¹⁴ (per point increase)	1.1 [1.1-1.2]

REFERENCES

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995;333:1581-1587
2. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. *N Engl J Med.* 1999;340:1781-1787
3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Jr., Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rT-PA stroke trials. *Lancet.* 2004;363:768-774
4. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soenne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. *Lancet.* 2007;369:275-282
5. Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD, for the Brain Attack Coalition. Recommendations for the establishment of primary stroke centers. *JAMA.* 2000;283:3102-3109

- 1
2
3 6. Klijn CJ, Hankey GJ. Management of acute ischaemic stroke: New guidelines from the
4 American Stroke Association and European Stroke Initiative. *Lancet Neurol.* 2003;2:698-
5
6 701
7
8
- 9
10 7. Adams HP, Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL,
11 Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI,
12 Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults
13 with ischemic stroke: A guideline from the American Heart Association/American Stroke
14 Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and
15 Intervention council, and the Atherosclerotic Peripheral Vascular Disease and Quality of
16 Care Outcomes in Research Interdisciplinary Working groups: The American Academy
17 of Neurology affirms the value of this guideline as an educational tool for neurologists.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 8. The Joint Commission Primary Stroke Center Certification.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
9. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. *JAMA.* 2000;283:1151-1158
10. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. *Neurology.* 2005;64:654-659
11. Qureshi AI, Suri MF, Nasar A, He W, Kirmani JF, Divani AA, Prestigiacomo CJ, Low RB. Thrombolysis for ischemic stroke in the united states: Data from National Hospital Discharge Survey 1999-2001. *Neurosurgery.* 2005;57:647-654; discussion 647-654

- 1
2
3 12. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates
4 of recombinant tissue plasminogen activator use: ICD-9 codes substantially
5 underestimate. *Stroke*. 2008;39:924-928
6
7
- 8
9
10 13. US Department of Health and Human Services Public Health Service and National
11 Center for Health Statistics. National Hospital Discharge Survey 1991-2006. Multi-year
12 public-use data file documentation.
13
14
- 15
16
17 14. Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-
18 CM administrative databases. *J Clin Epidemiol*. 1992;45:613-619
19
- 20
21
22 15. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D. Agostino R.
23 Stroke severity in atrial fibrillation. The Framingham study. *Stroke*. 1996;27:1760-1764
24
25
- 26
27 16. Barber P, Zhang J, Demchuk A, Hill M, Buchan A. Why are stroke patients excluded
28 from tPA therapy? An analysis of patient eligibility. *Neurology*. 2001;57:1739-1740
29
30
- 31
32 17. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM.
33 Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. *Arch*
34 *Neurol*. 2004;61:346-350
35
36
- 37
38
39 18. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J,
40 Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP, for The
41 Neuroscience I. Eligibility for recombinant tissue plasminogen activator in acute
42 ischemic stroke: A population-based study. *Stroke* 2004;35:27-29
43
44
- 45
46
47 19. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD. Tpa use for
48 stroke in the registry of the Canadian stroke network. *Can J Neurol Sci*. 2005;32:433-439
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, Brown AN. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: The influence of ethnicity. *Stroke*. 2001;32:1061-1068
 21. Saver JL, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P, Starkman S. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: Joint outcome table analysis of the ECASS 3 trial. *Stroke* 2009;40:2433-2437
 22. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: A meta-analysis of safety data. *Stroke*. 2003;34:2847-2850
 23. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneeweis S, Heiss WD. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. *Stroke*. 1998;29:1544-1549
 24. Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: An analysis of the Nationwide Inpatient Sample 1999 to 2002. *Stroke*. 2006;37:440-446
 25. Zweifler RM, Brody ML, Graves GC, U TT, Drinkard R, Cunningham S, Rothrock JF. Intravenous t-PA for acute ischemic stroke: Therapeutic yield of a stroke code system. *Neurology*. 1998;50:501-503
 26. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. *Arch Neurol*. 2001;58:2009-2013